In the first 100 days of the Trump administration, healthcare underwent significant shifts. As HHS Secretary Robert F. Kennedy Jr. promoted the "Make America Healthy Again" (MAHA) agenda, the workforce was reduced, and priorities for Medicaid and Medicare were redefined. Where do stakeholders position themselves, and what crucial aspects should they actively monitor?
The Washington Analysis, A CFRA Business, Healthcare team hosted a roundtable discussion to explore key issues impacting the healthcare industry. They examined the impact of recent leadership changes and restructuring at federal health agencies on regulation, stability, and workforce morale.
In this session, we discussed:
- The Congressional Outlook on Medicare Advantage, Medicare reimbursement (from the doc fix to site neutral), healthcare REITs, pharmacy benefit managers, pharmacies and drug pricing reform
- Medicaid: Examined how Medicaid reform proposals will disproportionately affects specific facilities, insurers and technology providers
- Medicare: Following the release of five proposed and two final payment rules, how reimbursement to facilities (Acute Care, Long Term Care Hospitals, Home Health, SNFs, Hospice) and insurers CHANGE
- Pharmaceuticals & MedTech: Outlook for tariffs, vaccines, reduction in funding for biomedical research, shakeup at the FDA, DTC Ads, reimbursement expectations for 2026
- Workforce Reduction: Highlight topics such as the impact of DOGE-related cuts on health agencies